When selecting an antidepressant for a patient on simvastatin and lisinopril, why would fluoxetine be eliminated from consideration?

When selecting an antidepressant for a patient on simvastatin and lisinopril, why would fluoxetine be eliminated from consideration?

• A. both medications are CYP450 3A4 inhibitors
• B. both medications are CYP450 3A4 substrates
• C. one is a CYP450 3A4 substrate and the other is a CYP450 3A4 inducer
• D. one is a CYP450 3A4 substrate and the other is a CYP450 3A4 inhibitor

Answer: (D)

Fluoxetine would be eliminated from consideration because it is a strong inhibitor of the CYP450 2D6 enzyme, which can lead to increased levels of other medications that are metabolized through this pathway. In the context of the patient taking simvastatin and lisinopril, fluoxetine's inhibitory effects on CYP450 enzymes could potentially lead to increased serum concentrations of simvastatin, which raises the risk of statin-related side effects, such as myopathy or rhabdomyolysis. In addition to fluoxetine, lisinopril is not metabolized by the CYP450 system, but the concern regarding fluoxetine lies in its potential to interact with other medications that are substrates of the same metabolic pathway as simvastatin. The use of a CYP450 3A4 inhibitor like fluoxetine could exacerbate this interaction, requiring heightened caution. When evaluating the listed options, the correct reasoning focuses on the interactions involving fluoxetine as a CYP450 2D6 inhibitor, rather than interactions solely related to CYP450 3A4, which is the primary enzyme for simvastatin and one that can be affected by various drugs, including some antidepressants. This pharmacological understanding helps in ensuring the safety and efficacy of pharmacotherapy

Fluoxetine would be eliminated from consideration because it is a strong inhibitor of the CYP450 2D6 enzyme, which can lead to increased levels of other medications that are metabolized through this pathway. In the context of the patient taking simvastatin and lisinopril, fluoxetine's inhibitory effects on CYP450 enzymes could potentially lead to increased serum concentrations of simvastatin, which raises the risk of statin-related side effects, such as myopathy or rhabdomyolysis.

In addition to fluoxetine, lisinopril is not metabolized by the CYP450 system, but the concern regarding fluoxetine lies in its potential to interact with other medications that are substrates of the same metabolic pathway as simvastatin. The use of a CYP450 3A4 inhibitor like fluoxetine could exacerbate this interaction, requiring heightened caution.

When evaluating the listed options, the correct reasoning focuses on the interactions involving fluoxetine as a CYP450 2D6 inhibitor, rather than interactions solely related to CYP450 3A4, which is the primary enzyme for simvastatin and one that can be affected by various drugs, including some antidepressants. This pharmacological understanding helps in ensuring the safety and efficacy of pharmacotherapy